About Variant Bio
Variant Bio is a company based in Brooklyn (United States) founded in 2018 by Stephane Castel and Kaja Wasik. Variant Bio has raised $127.74 million across 3 funding rounds from investors including Lux Capital. Variant Bio offers products and services including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations. Variant Bio operates in a competitive market with competitors including Viome, Invitae, Color, Everlywell and Newtopia, among others.
- Headquarter Brooklyn, United States
- Founders Stephane Castel, Kaja Wasik
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$127.74 M (USD)
in 3 rounds
-
Latest Funding Round
$105 M (USD), Series B
Nov 17, 2021
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Variant Bio
Variant Bio offers a comprehensive portfolio of products and services, including Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations.
Platform for analyzing human genes to identify therapy targets.
Services for generating genomic data to support drug development.
Programs for ethical partnerships in genomics and benefit sharing.
People of Variant Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Variant Bio
Variant Bio has successfully raised a total of $127.74M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $105 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Variant Bio
Variant Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lux Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked |
Investor details for Variant Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Variant Bio
Investment portfolio details for Variant Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Variant Bio
Detailed financials for Variant Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Variant Bio Comparisons
Peer comparison for Variant Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Variant Bio
Variant Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Viome, Invitae, Color, Everlywell and Newtopia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Machine learning-based bioinformatics solutions for health insights are provided.
|
|
| Locked | Locked | Locked |
Home-based genetic tests for detecting diseases are provided to individuals.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
At-home health tests for biomarkers, nutrition, and hormone analysis.
|
|
| Locked | Locked | Locked |
Health management platform is provided for employers and insurers.
|
Detailed competitors of Variant Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Variant Bio
Complete news archive for Variant Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Variant Bio
Variant Bio was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Variant Bio is headquartered in Brooklyn, United States. It is registered at Brooklyn, New York, United States.
Andrew Farnum is the current CEO of Variant Bio.
Variant Bio is a funded company, having raised a total of $127.74M across 3 funding rounds to date.
Variant Bio was founded in 2018 and is headquartered in Brooklyn, United States. The company operates in the biotechnology sector, focusing on genomics to address rare diseases. A platform is provided for detecting human genetic diversity, enabling the development of targeted treatment solutions. Services emphasize personalized therapeutics derived from genetic analysis to support therapeutic advancements in underserved medical areas.
Variant Bio offers Genomic Discovery Platform, Data Generation Services, and Ethical Research Collaborations.
Variant Bio has 1 investor. Key investors include Lux Capital.